Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: An animal model

Schizophrenia Research

Volumn 146, Issue 1-3, 2013, Pages 162-169

  Guenette, Melanie Dawn ^a   Giacca, Adria ^a   Hahn, Margaret ^a,b   Teo, Celine ^b   Lam, Loretta ^a   Chintoh, Araba ^a,b   Arenovich, Tamara ^b   Remington, Gary ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adrenergic; Atypical antipsychotics; Diabetes; Glucose metabolism; Insulin; Receptor binding; Schizophrenia; Serotonergic

Indexed keywords

6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR; ATYPICAL ANTIPSYCHOTIC AGENT; C PEPTIDE; GLUCOSE; IDAZOXAN; INSULIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PRAZOSIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR; VOLINANSERIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE METABOLISM; IN VIVO STUDY; INSULIN RELEASE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

ADRENERGIC AGENTS; ANIMALS; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; HYPERGLYCEMIA; INSULIN; MALE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC; RECEPTORS, SEROTONIN; SEROTONIN AGENTS; TIME FACTORS; WEIGHT GAIN;

EID: 84875946866     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.02.023     Document Type: Article

References (67)

1. Ahren B., Jarhult J., Lundquist I. Enhancement of insulin secretion during selective blockade of alpha 1- and alpha 2-adrenoceptors in the rat: effects of somatostatin. Acta Physiol. Scand. 1982, 115:257-260.
2. Assie M.B., Carilla-Durand E., Bardin L., Maraval M., Aliaga M., Malfetes N., Barbara M., Newman-Tancredi A. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063. Eur. J. Pharmacol. 2008, 592:160-166.
3. Belahsen R., Deshaies Y. Involvement of insulinemia in the postprandial hypotriacylglycerolemia induced by prazosin in the rat. Metabolism 1993, 42:1301-1309.
4. Bergman R.N., Finegood D.T., Kahn S.E. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur. J. Clin. Invest. 2002, 32(Suppl. 3):35-45.
5. Boyda H.N., Tse L., Procyshyn R.M., Wong D., Wu T.K., Pang C.C., Barr A.M. A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:945-954.
6. Boyda H.N., Procyshyn R.M., Tse L., Wong D., Pang C.C., Honer W.G., Barr A.M. Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats. Neuropharmacology 2012, 62:1391-1400.
7. Canadian Pharmacists Association Compendium of Pharmaceuticals and Specialties (CPS) 2012, Canadian Pharmacists Association, Ottawa.
8. Chaouloff F., Jeanrenaud B. 5-HT1A and alpha-2 adrenergic receptors mediate the hyperglycemic and hypoinsulinemic effects of 8-hydroxy-2-(di-n-propylamino)tetralin in the conscious rat. J. Pharmacol. Exp. Ther. 1987, 243:1159-1166.
9. Chaouloff F., Baudrie V., Laude D. Evidence that 5-HT1A receptors are involved in the adrenaline-releasing effects of 8-OH-DPAT in the conscious rat. Naunyn Schmiedebergs Arch. Pharmacol. 1990, 341:381-384.
10. Chaouloff F., Laude D., Baudrie V. Effects of the 5-HT1C/5-5-HT2 receptor agonists DOI and alpha-methyl-5-HT on plasma glucose and insulin levels in the rat. Eur. J. Pharmacol. 1990, 187:435-443.
11. Chemel B.R., Roth B.L., Armbruster B., Watts V.J., Nichols D.E. WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology 2006, 188:244-251.
12. Cheng J.T., Chi T.C., Liu I.M. Activation of adenosine A1 receptors by drugs to lower plasma glucose in streptozotocin-induced diabetic rats. Auton. Neurosci. 2000, 83:127-133.
13. Cheng J.T., Liu I.M., Yen S.T., Chen P.C. Role of alpha1A-adrenoceptor in the regulation of glucose uptake into white adipocyte of rats in vitro. Auton. Neurosci. 2000, 84:140-146.
14. Chintoh A.F., Mann S.W., Lam L., Lam C., Cohn T.A., Fletcher P.J., Nobrega J.N., Giacca A., Remington G. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J. Clin. Psychopharmacol. 2008, 28:494-499.
15. Chintoh A.F., Mann S.W., Lam T.K.T., Giacca A., Remington G. Insulin resistance following continuous, chronic olanzapine treatment: an animal model. Schizophr. Res. 2008, 104:23-30.
16. Chintoh A.F., Mann S.W., Lam L., Giacca A., Fletcher P., Nobrega J., Remington G. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophr. Res. 2009, 108:127-133.
17. DeFronzo R.A., Tobin J.D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 1979, 237:E214-223.
18. Elahi D. In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance. Diabetes Care 1996, 19:278-286.
19. Fajardo N., Deshaies Y. Glucose tolerance and postprandial glucose and insulin kinetics in rats with short- and long-term alpha 1-adrenergic blockade. J. Cardiovasc. Pharmacol. 1996, 28(3):402-408.
20. Fletcher P.J., Tampakeras M., Sinyard J., Higgins G.A. Opposing effects of 5-HT(2A) and 5-HT(2C) receptor antagonists in the rat and mouse on premature responding in the five-choice serial reaction time test. Psychopharmacology 2007, 195:223-234.
21. Fulbright A., Breedlove K. Complete resolution of olanzapine-induced diabetic ketoacidosis. J. Pharm. Pract. 2006, 19:255-258.
22. Gatta B., Rigalleau V., Gin H. Diabetic ketoacidosis with olanzapine treatment. Diabetes Care 1999, 22:1002-1003.
23. Gilles M., Wilke A., Kopf D., Nonell A., Lehnert H., Deuschle M. Antagonism of the serotonin 5-HT-2 receptor and insulin sensitivity: implications for atypical antipsychotics. Psychosom. Med. 2005, 67:748-751.
24. Gregersen H., Jensen S.L., Ahren B. An alpha 1-adrenoceptor-sensitive mechanism is responsible for the adrenergic inhibition of insulin secretion in the pig pancreas. Eur. J. Pharmacol. 1991, 200:365-367.
25. Gylfe E. Association between 5-hydroxytryptamine release and insulin secretion. J. Endocrinol. 1978, 78:239-248.
26. Hahn M., Chintoh A., Giacca A., Xu L., Lam L., Mann S., Fletcher P., Guenette M., Cohn T., Wolever T., Arenovich T., Remington G. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model. Schizophr. Res. 2011, 131:90-95.
27. Hajduch E., Rencurel F., Balendran A., Batty I.H., Downes C.P., Hundal H.S. Serotonin (5-Hydroxytryptamine), a novel regulator of glucose transport in rat skeletal muscle. J. Biol. Chem. 1999, 274:13563-13568.
28. Hayashi A., Sonoda R., Kimura Y., Takasu T., Suzuki M., Sasamata M., Miyata K. Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats. Brain Res. 2004, 1011:221-227.
29. Houseknecht K.L., Robertson A.S., Zavadoski W., Gibbs E.M., Johnson D.E., Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007, 32:289-297.
30. Jackson H.C., Needham A.M., Hutchins L.J., Mazurkiewicz S.E., Heal D.J. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br. J. Pharmacol. 1997, 121:1758-1762.
31. Joordens R.J., Hijzen T.H., Olivier B. The effects of 5-HT1A receptor agonists, 5-HT1A receptor antagonists and their interaction on the fear-potentiated startle response. Psychopharmacology 1998, 139:383-390.
32. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur. J. Pharmacol. 2002, 441:137-140.
33. Kroeze W.K., Hufeisen S.J., Popadak B.A., Renock S.M., Steinberg S., Ernsberger P., Jayathilake K., Meltzer H.Y., Roth B.L. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003, 28:519-526.
34. Leysen J.E., Awouters F., Kennis L., Laduron P.M., Vandenberk J., Janssen P.A. Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci. 1981, 28:1015-1022.
35. Macfarlane D., Fisher M. A combination of atypical antipsychotics and diabetic ketoacidosis. Pract. Diab. Int. 2006, 23:205-206.
36. Makhzoumi Z.H., McLean L.P., Lee J.H., Ibe A.I. Diabetic ketoacidosis associated with aripiprazole. Pharmacotherapy 2008, 28:1198-1202.
37. McCall R.B., Harris L.T. 5-HT2 receptor agonists increase spontaneous sympathetic nerve discharge. Eur. J. Pharmacol. 1988, 151:113-116.
38. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., Meltzer H.Y., Hsiao J., Scott Stroup T., Lieberman J.A. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005, 80:19-32.
39. Melkersson K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur. Neuropsychopharmacol. 2004, 14:115-119.
40. Meltzer H.Y., Matsubara S., Lee J.C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol. Bull. 1989, 25:390-392.
41. Murashita M., Kusumi I., Hosoda H., Kangawa K., Koyama T. Acute administration of clozapine concurrently increases blood glucose and circulating plasma ghrelin levels in rats. Psychoneuroendocrinology 2007, 32:777-784.
42. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl. 1):1-93.
43. Nonogaki K., Strack A.M., Dallman M.F., Tecott L.H. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat. Med. 1998, 4:1152-1156.
44. Paulmann N., Grohmann M., Voigt J.P., Bert B., Vowinckel J., Bader M., Skelin M., Jevsek M., Fink H., Rupnik M., Walther D.J. Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation. PLoS Biol. 2009, 7:e1000229.
45. Physicians' Desk Reference, 2012. 66th ed. Thomson PDR, Montvale, NJ.
46. Pi-Sunyer F.X. Medical hazards of obesity. Ann. Intern. Med. 1993, 119:655-660.
47. Rashid J., Starer P.J., Javaid S. Pancreatitis and diabetic ketoacidosis with quetiapine use. Psychiatry (Edgmont) 2009, 6:34-37.
48. Rattigan S., Clark M.G., Barrett E.J. Acute vasoconstriction-induced insulin resistance in rat muscle in vivo. Diabetes 1999, 48:564-569.
49. Richmond J.E., Codignola A., Cooke I.M., Sher E. Calcium- and barium-dependent exocytosis from the rat insulinoma cell line RINm5F assayed using membrane capacitance measurements and serotonin release. Pflugers Arch. 1996, 432:258-269.
50. Rosengren A.H., Jokubka R., Tojjar D., Granhall C., Hansson O., Li D.Q., Nagaraj V., Reinbothe T.M., Tuncel J., Eliasson L., Groop L., Rorsman P., Salehi A., Lyssenko V., Luthman H., Renstrom E. Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes. Science 2010, 327:217-220.
51. Rubi B., Ljubicic S., Pournourmohammadi S., Carobbio S., Armanet M., Bartley C., Maechler P. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J. Biol. Chem. 2005, 280:36824-36832.
52. Satin L.S., Kinard T.A. Neurotransmitters and their receptors in the islets of Langerhans of the pancreas: what messages do acetylcholine, glutamate, and GABA transmit?. Endocrine 1998, 8:213-223.
53. Savontaus E., Fagerholm V., Rahkonen O., Scheinin M. Reduced blood glucose levels, increased insulin levels and improved glucose tolerance in alpha2A-adrenoceptor knockout mice. Eur. J. Pharmacol. 2008, 578:359-364.
54. Smith P.A., Proks P., Ashcroft F.M. Quantal analysis of 5-hydroxytryptamine release from mouse pancreatic beta-cells. J. Physiol. 1999, 521:651-664.
55. Smith G.C., Chaussade C., Vickers M., Jensen J., Shepherd P.R. Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia 2008, 51:2309-2317.
56. Sprouse J.S., Reynolds L.S., Braselton J.P., Rollema H., Zorn S.H. Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology 1999, 21:622-631.
57. Starrenburg F.C., Bogers J.P. How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. Eur. Psychiatry 2009, 24:164-170.
58. Tecott L.H., Sun L.M., Akana S.F., Strack A.M., Lowenstein D.H., Dallman M.F., Julius D. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995, 374:542-546.
59. Uvnas-Moberg K., Ahlenius S., Alster P., Hillegaart V. Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin and glucagon in the rat. Neuroendocrinology 1996, 63:269-274.
60. Wang B., Chehab F.F. Deletion of the serotonin 2c receptor from transgenic mice overexpressing leptin does not affect their lipodystrophy but exacerbates their diet-induced obesity. Biochem. Biophys. Res. Commun. 2006, 351:418-423.
61. Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf. 2001, 24:59-73.
62. Wirshing D.A., Spellberg B.J., Erhart S.M., Marder S.R., Wirshing W.C. Novel antipsychotics and new onset diabetes. Biol. Psychiatry 1998, 44:778-783.
63. Wirshing D.A., Wirshing W.C., Kysar L., Berisford M.A., Goldstein D., Pashdag J., Mintz J., Marder S.R. Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychiatry 1999, 60:358-363.
64. Xu Y., Jones J.E., Kohno D., Williams K.W., Lee C.E., Choi M.J., Anderson J.G., Heisler L.K., Zigman J.M., Lowell B.B., Elmquist J.K. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron 2008, 60:582-589.
65. Zhou L., Sutton G.M., Rochford J.J., Semple R.K., Lam D.D., Oksanen L.J., Thornton-Jones Z.D., Clifton P.G., Yueh C.Y., Evans M.L., McCrimmon R.J., Elmquist J.K., Butler A.A., Heisler L.K. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab. 2007, 6:398-405.
66. Zillich A.J., Garg J., Basu S., Bakris G.L., Carter B.L. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006, 48:219-224.
67. Zipursky R.B., Gu H., Green A.I., Perkins D.O., Tohen M.F., McEvoy J.P., Strakowski S.M., Sharma T., Kahn R.S., Gur R.E., Tollefson G.D., Lieberman J.A. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br. J. Psychiatry 2005, 187:537-543.